SNOT-22 response to treatment
A total of 54% and 32% of patients treated with mepolizumab and placebo achieved a ≥ 28-point improvement in SNOT-22 total scores, respectively (Additional file Probability of patients reporting ≥ 28-point improvement from baseline in SNOT-22 total score over time. *Change from baseline in SNOT-22 total and domain scores at Week 52. Estimates are based on weighting applied to each level of class variable determined from observed proportions. 